TNFSF10 and cancer: The authors confirmed TIMP3 as a miR-221/222 target in HCC-derived cancer cells and showed that as a consequence of miR-221-mediated TIMP3 degradation, these cells were resistant to treatment with TNF-related, apoptosis-inducing ligand (TRAIL).